The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform

Mats Borjesson - One of the best experts on this subject based on the ideXlab platform.

Alessandro Biffi - One of the best experts on this subject based on the ideXlab platform.

Josef Niebauer - One of the best experts on this subject based on the ideXlab platform.

  • Brief recommendations for participation in leisure time or competitive sports in athletes-patients with coronary artery disease: Summary of a Position Statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (
    European journal of preventive cardiology, 2019
    Co-Authors: Mats Borjesson, Mikael Dellborg, Josef Niebauer, Andre Lagerche, Christian Schmied, Erik Ekker Solberg, Martin Halle, Paolo Emilio Adami, Alessandro Biffi, Francois Carré
    Abstract:

    This paper presents a brief summary of the recommendations from the Sports Cardiology section of the European Association of Preventive Cardiology (EAPC) on sports-participation in patients with coronary artery disease, coronary artery anomalies or spontaneous dissection of the coronary arteries, all entities being associated with myocardial ischaemia.1 Given the wealth of evidence supporting the benefits of exercise for primary and secondary prevention of coronary artery disease, individuals should be restricted from competitive sport only when a substantial risk of adverse event or disease progression is present. These recommendations aim to encourage regular physical activity including participation in sports and, with reasonable precaution, ensure a high level of safety for all individuals with coronary artery disease. The present document is based on available current evidence, but in most instances because of lack of evidence, also on clinical experience and expert opinion.

  • recommendations for participation in leisure time or competitive sports in athletes patients with coronary artery disease a position statement from the sports Cardiology section of the european association of Preventive Cardiology eapc
    European Heart Journal, 2019
    Co-Authors: Mats Borjesson, Mikael Dellborg, Josef Niebauer, Andre Lagerche, Christian Schmied, Erik Ekker Solberg, Martin Halle, Paolo Emilio Adami, Alessandro Biffi
    Abstract:

    This paper presents a brief summary of the recommendations from the Sports Cardiology section of the European Association of Preventive Cardiology (EAPC) on sports-participation in patients with co...

  • the european association of Preventive Cardiology exercise prescription in everyday practice and rehabilitative training expert tool a digital training and decision support system for optimized exercise prescription in cardiovascular disease concept
    European Journal of Preventive Cardiology, 2017
    Co-Authors: Dominique Hansen, Josef Niebauer, Massimo F. Piepoli, Paul Dendale, Karin Coninx, Luc Vanhees, Veronique Cornelissen, Roberto F E Pedretti, Eva Geurts, Gustavo Rovelo Ruiz
    Abstract:

    Background Exercise rehabilitation is highly recommended by current guidelines on prevention of cardiovascular disease, but its implementation is still poor. Many clinicians experience difficulties in prescribing exercise in the presence of different concomitant cardiovascular diseases and risk factors within the same patient. It was aimed to develop a digital training and decision support system for exercise prescription in cardiovascular disease patients in clinical practice: the European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool. Methods EXPERT working group members were requested to define (a) diagnostic criteria for specific cardiovascular diseases, cardiovascular disease risk factors, and other chronic non-cardiovascular conditions, (b) primary goals of exercise intervention, (c) disease-specific prescription of exercise training (intensity, frequency, volume, type, session and programme duration), and (d) exercise training safety advices. The impact of exercise tolerance, common cardiovascular medications and adverse events during exercise testing were further taken into account for optimized exercise prescription. Results Exercise training recommendations and safety advices were formulated for 10 cardiovascular diseases, five cardiovascular disease risk factors (type 1 and 2 diabetes, obesity, hypertension, hypercholesterolaemia), and three common chronic non-cardiovascular conditions (lung and renal failure and sarcopaenia), but also accounted for baseline exercise tolerance, common cardiovascular medications and occurrence of adverse events during exercise testing. An algorithm, supported by an interactive tool, was constructed based on these data. This training and decision support system automatically provides an exercise prescription according to the variables provided. Conclusion This digital training and decision support system may contribute in overcoming barriers in exercise implementation in common cardiovascular diseases.

Nathan D. Wong - One of the best experts on this subject based on the ideXlab platform.

  • Comprar Preventive Cardiology: Companion to Braunwald's Heart Disease Expert Consult - Online and Print | Roger Blumenthal | 9781437713664 | Saunders
    2020
    Co-Authors: Roger Blumenthal, Joanne M. Foody, Nathan D. Wong
    Abstract:

    Tienda online donde Comprar Preventive Cardiology: Companion to Braunwald's Heart Disease Expert Consult - Online and Print al precio 142,80 € de Roger Blumenthal | JoAnne Foody | Nathan D. Wong, tienda de Libros de Medicina, Libros de Cardiologia - Cardiologia general

  • cardiovascular risk assessment the foundation of Preventive Cardiology
    American Journal of Preventive Cardiology, 2020
    Co-Authors: Nathan D. Wong
    Abstract:

    Abstract The foundation of Preventive Cardiology begins with knowing the patient’s baseline cardiovascular disease (CVD) risk from which the patient-clinician risk discussion informs on the best ways to lower risk through lifestyle management, as well as a decision about the initiation and intensity of pharmacologic therapy. Global CVD risk assessment involves estimation of cardiovascular risk using a basic panel of risk factors. The Framingham Heart Study championed the first such risk scores, followed by others around the world. Most recently, the Pooled Cohort Equations (PCE) have been recommended in the United States as a starting point in CVD risk assessment. Persons at low ( 20%) 10-year risk are recommended for both lifestyle and pharmacologic therapy to reduce risk. Assessing the presence of one or more “risk enhancing” factors is intended to inform the treatment decision in those at borderline (5-

  • most important advances in Preventive Cardiology during this past decade viewpoint from the american society for Preventive Cardiology
    Trends in Cardiovascular Medicine, 2019
    Co-Authors: Nathan D. Wong, Peter P Toth, Ezra A Amsterdam
    Abstract:

    Abstract The rapidly expanding field of Preventive Cardiology has brought with it several major advances in the past decade. Changes in guidelines for cholesterol mangement focusing on the identification of “statin eligible groups” and removal of actual low-density lipoprotein cholesterol (LDL-C) targets, in particular, as well as lower targets for blood pressure in updated hypertension guidelines, have made a major impact on healthcare. The availability of the sodium glucose transport protein-2 (SGLT2) inhibitors and glucagon-like peptide -1 receptor antagonists (GLP1-RA) for managing diabetes have shifted our focus in diabetes care beyond glucose lowering to addressing cardiovascular risk reduction. While many prior trials of fish oil therapy have failed to show benefit, the recent Reduction of Cardiovascular Events With EPA – Intervention Trial (REDUCE-IT) testing the efficacy of icosapent ethyl has shown dramatic benefit in further addressing residual atherosclerotic cardiovascular disease (ASCVD) risk beyond statin therapy not only in those with known ASCVD, but also in diabetic patients with multiple risk factors. The past decade also ushered in confirmation of the inflammation hypothesis of atherosclerosis with the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) using canakinumab, despite the fact the therapy was not approved by the Food and Drug Administration (FDA) for cardiovascular risk reduction. Also, to improve our understanding of heart disease in women, the emergence of novel concepts of ischemia or myocardial infarction in those with normal or nonobstructive atherosclerotic disease has been a major advance. Moreover, the past decade brought the emergence of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody therapy and the cardiovascular risk reduction benefits seen in the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES) trials, providing further evidence-based therapy for additional reduction of ASCVD risk beyond statin therapy. The PCSK9 monoclonal antibodies have facilitated the attainment of LDL-C levels never previously thought possible. Finally with the mRNA interference therapy inclisiran in development, we may soon have a “vaccine-like” approach for addressing dyslipidemia and atherosclerosis.

  • epidemiological studies of chd and the evolution of Preventive Cardiology
    Nature Reviews Cardiology, 2014
    Co-Authors: Nathan D. Wong
    Abstract:

    Cardiovascular diseases (CVDs) cause nearly one-third of all deaths worldwide. Coronary heart disease (CHD) accounts for the greatest proportion of CVDs, and risk factors such as hypertension, cigarette smoking, diabetes mellitus or elevated glucose level, elevated cholesterol levels, and obesity or being overweight are the top six causes of death globally. Ecological and population-based longitudinal studies, conducted globally or within individual countries, have established the role of traditional and novel risk factors and measures of subclinical disease in the prediction of CHD. Risk assessment with short-term or long-term risk prediction algorithms can help to identify individuals who would benefit most from risk-factor interventions. Evaluation of novel risk factors and screening for subclinical atherosclerosis can also help to identify individuals at highest cardiovascular risk. Prevention of CHD focuses on identifying and managing risk factors at both the population and individual levels through primordial, primary, and secondary prevention. Epidemiological studies have provided the hypotheses for subsequent clinical trials that have documented the efficacy of risk-factor interventions, which are the basis of Preventive Cardiology. Future research efforts will determine the screening and intervention strategies that have the greatest effect on CHD prevention.

  • a point by point response to recent arguments against the use of statins in primary prevention this statement is endorsed by the american society for Preventive Cardiology
    Clinical Cardiology, 2012
    Co-Authors: Parag H Joshi, Nathan D. Wong, Sameer Chaudhari, Michael J Blaha, Steven R Jones, Seth S Martin, Wendy S Post, Christopher P Cannon, Gregg C Fonarow, Ezra A Amsterdam
    Abstract:

    Recently, a debate over the merits of statin therapy in primary prevention was published in the Wall Street Journal. The statin opponent claimed that statins should only be used in secondary prevention and never in any primary-prevention patients at risk for cardiovascular events. In this evidence-based rebuttal to those claims, we review the evidence supporting the efficacy of statin therapy in primary prevention. Cardiovascular risk is a continuum in which those at an elevated risk of events stand to benefit from early initiation of therapy. Statins should not be reserved until after a patient suffers the catastrophic consequences of atherosclerosis. Contrary to the assertions of the statin opponent, this principle has been demonstrated through reductions in heart attacks, strokes, and mortality in numerous randomized controlled primary-prevention statin trials. Furthermore, data show that once a patient tolerates the initial treatment period, the few side effects that subsequently emerge are largely reversible. Accordingly, every major guidelines committee endorses statin use in secondary prevention and selectively in primary prevention for those with risk factors. The foundation for prevention remains increased physical activity, better dietary habits, and smoking cessation. However, prevention of heart attacks, strokes, and death from cardiovascular disease does not have to be all or none—all statin or all lifestyle. In selected at-risk individuals, the combination of pharmacotherapy and lifestyle changes is more effective than either alone. Future investigation in prevention should focus on improving our ability to identify these at-risk individuals. Drs Amsterdam, Blumenthal, and Wong serve on the board of directors and/or are officers of the American Society for Preventive Cardiology. Dr Wong has received research support from Merck and Bristol Myers-Squibb and advisory board consultant fees from Merck in the past 12 months. Dr Cannon is a senior investigator in the TIMI Study Group; has received research support from Accumetrics, AstraZeneca, GlaxoSmithKline, Merck, Essentialis, and Takeda; has donated advisory board consultant fees to charity from Bristol-Myers Squibb/Sanofi, Novartis, and Alnylam; has received honoraria for development of independent educational symposia from Pfizer and AstraZeneca; and has equity in Automedics Medical Systems. Dr Jones has received research support and advisory board consultant fees from Atherotech Diagnostics Lab and has served as a consultant for Amylin Pharmaceuticals. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Patrick E. Mcbride - One of the best experts on this subject based on the ideXlab platform.

  • current status of Preventive Cardiology training among united states Cardiology fellowships and comparison to training guidelines
    American Journal of Cardiology, 2012
    Co-Authors: Quinn R Pack, Patrick E. Mcbride, Steven J Keteyian, Douglas W Weaver
    Abstract:

    We evaluated Preventive Cardiology education in United States Cardiology fellowship programs and their adherence to Core Cardiovascular Training Symposium training guidelines, which recommend 1 month of training, faculty with expertise, and clinical experience in cardiac rehabilitation, lipid disorder management, and diabetes management as a part of the prevention curricula. We sent an anonymous survey to United States Cardiology program directors and their chief fellow. The survey assessed the program curricula, rotation structure, faculty expertise, obstacles, and recommended improvements. The results revealed that 24% of surveyed programs met the Core Cardiovascular Training Symposium guidelines with a dedicated 1-month rotation in Preventive Cardiology, 24% had no formalized training in Preventive Cardiology, and 30% had no faculty with expertise in Preventive Cardiology, which correlated with fewer rotations in prevention than those with specialized faculty (p = 0.009). Fellows rotated though the following experiences (% of programs): cardiac rehabilitation, 71%; lipid management, 37%; hypertension, 15%; diabetes, 7%; weight management/obesity, 6%; cardiac nutrition, 6%; and smoking cessation, 5%. The program directors cited "lack of time" as the greatest obstacle to providing Preventive Cardiology training and the chief fellows reported "lack of a developed curriculum" (p = 0.01). The most recommended improvement was for the American College of Cardiology to develop a web-based curriculum/module. In conclusion, most surveyed United States Cardiology training programs currently do not adhere to basic Preventive cardiovascular medicine Core Cardiovascular Training Symposium recommendations. Additional attention to developing curricular content and structure, including the creation of an American College of Cardiology on-line knowledge module might improve fellowship training in Preventive Cardiology.

  • subspecialty training in Preventive Cardiology the current status and discoverable fellowship programs
    Clinical Cardiology, 2012
    Co-Authors: Quinn R Pack, Steven J Keteyian, Patrick E. Mcbride
    Abstract:

    Background Preventive Cardiology is currently not an American Board of Medical Specialties-recognized subspecialty. However, several programs offer non-accredited fellowships throughout the country. No source currently exists listing all available programs, and finding programs requires time-intensive search strategies. Our aim was to find all current Preventive Cardiology fellowships in the United States and describe their basic structure, duties, and faculty. Methods We searched the Internet, contacted national organizations, and networked through any institution thought likely to have a fellowship. Results We found 15 programs currently offering subspecialty training in Preventive Cardiology but with considerably different styles, structures, duties, clinical time, lengths, and hosting departments. Conclusions We provided a list of these programs and discussed the implications for the future of formal subspecialty Preventive Cardiology education.

  • Teaching Preventive Cardiology in primary care: an integrated curricular approach.
    American Journal of Preventive Medicine, 1990
    Co-Authors: Patrick E. Mcbride
    Abstract:

    : Education in Preventive Cardiology is an essential element of any primary care curriculum. Gaps in primary care training and delivery of Preventive services are well documented and reinforce the need for curricular evaluation and innovation. The Preventive Cardiology Academic Award program provides a network of resources and information for enhancing a Preventive Cardiology curriculum. This paper describes an approach to the design, implementation, and evaluation of a Preventive Cardiology curriculum for primary care physician training. A sequence of instruction is presented to provide a framework for provision of knowledge, confidence, and skills for integration into traditional physician education. Basic components of Preventive Cardiology and program innovations are highlighted.